查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1868923

核酸疗法CDMO市场按治疗类型、服务类型、治疗应用和最终用户划分－2025-2032年全球预测

Nucleic Acid Therapeutics CDMO Market by Therapeutics Type, Service Type, Therapeutic Applications, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，核酸疗法的合约开发和生产组织 (CDMO) 市场将成长至 261.4 亿美元，复合年增长率为 11.71%。

关键市场统计数据
基准年 2024 107.7亿美元
预计年份：2025年 120亿美元
预测年份 2032 261.4亿美元
复合年增长率 (%) 11.71%

随着CDMO在加速发展的策略角色中扮演越来越重要的角色，它们将助力复杂核酸疗法的开发，以满足日益增长的科学和监管需求。

核酸治疗药物的合约开发与生产（CDMO）领域已进入技术快速融合、战略重要性日益凸显的阶段，这对研发方和合约合作伙伴都至关重要。治疗模式、生产平台和监管要求的最新进展，已使CDMO从单纯的供应商转变为对专案进度和临床可行性具有重大影响的策略合作伙伴。随着研发方不断探索日益复杂的结构，包括修饰寡核苷酸、病毒载体和脂质奈米颗粒製剂，对专业製程知识、严格的品管和灵活的生产能力的需求也日益增长。

揭示正在改变核酸治疗领域研发、生产实践、监管预期和伙伴关係模式的多方面颠覆性力量

核酸疗法正在重塑治疗模式，这项变革正推动研发、生产和商业化等各环节发生连锁反应。技术创新正在推动分子设计、生产和测试方式的模式转移，模组化和连续生产方法在许多应用中取代了传统的间歇式生产。同时，数位化製程控制和先进的分析技术正在加强品质系统和製程理解的基础。这些变化正在拓展合约研发生产机构（CDMO）所需的能力范围，要求其投资于专用设备、即时监控能力和多学科人才。

评估2025年关税调整对核酸治疗供应链的采购、供应商合格和营运风险管理的影响

美国2025年关税的实施和调整为核酸治疗药物生产的供应和成本模式引入了新的变数。影响进口原料、特殊试剂和某些生产设备的关税措施迫使生产商和赞助公司重新评估筹资策略，并加快替代供应商的资格认证。因此，采购团队正在加强对供应商韧性和地理多元化的审查，而生产负责人则在权衡近岸外包、在岸外包和维持海外合作关係之间的利弊。

从模式、服务类型、应用和最终用户群等方面推导出策略意义，以指导能力投资和伙伴关係关係结构。

透过沿着多个细分维度分析需求和产能，可以更清楚地了解市场格局。从治疗方法类型来看，DNA疗法和RNA疗法之间的差异对生产流程、分析测试范式和监管环节都具有重要意义。 RNA疗法需要专门的製剂技术和低温运输能力，而DNA疗法在上游工程和下游纯化方面则面临独特的挑战。从服务角度来看，分析测试和品管、生产/包装/分销以及製程开发/最佳化之间的相互作用决定了价值所在。能够整合端到端服务的机构可以缩短週期并减少交接环节，而精通高技术任务和方法开发的专业技能仍然至关重要。

解读区域生态系统、法规结构与能力发展对美洲、欧洲、中东和非洲以及亚太地区CDMO战略定位的影响

区域趋势持续影响CDMO产业的策略决策，每个区域的需求和产能都受到不同因素的影响。在美洲，蓬勃发展的生物技术生态系统、创业投资投资以及大量后期临床计画推动了对可扩展生产和严格监管合规性的需求。这种环境促使申办方和生产合作伙伴在临床到商业化过渡计画中密切合作，这就要求对符合GMP标准的设施、监管事务专业知识和供应链韧性进行投资。

了解CDMO如何透过技术深度、一体化服务和客户客製化的商业结构来脱颖而出，以及它们所采用的竞争和伙伴关係模式。

在核酸治疗生态系中，企业间的竞争日益凸显，其竞争优势体现在对治疗模式的深入了解、综合服务能力以及透过成熟的监管实践降低临床转化风险的能力。领先的供应商正透过投资平台技术来实现差异化，这些技术能够加快製程开发速度、提高产品品质并简化规模化生产路径。单纯的生产能力已不再是决定性因素；相反，那些将完善的品质系统、先进的分析技术以及成功的技术转移经验相结合的企业，才能获得竞争优势。

经营团队为提升核酸治疗药物研发的可靠性，必须解决以下实际策略问题：加强伙伴关係、提高供应链韧性、数位化品管和人力资源发展。

产业领导者和专案发起人应采取一系列切实可行的措施，使其营运、伙伴关係和投资计画与核酸疗法开发不断变化的实际情况相适应。首先，应优先建立联合开发框架，正式确立发起人和生产商之间的早期合作，以加速製程转移并最大限度地减少后续环节的意外情况。设定共同的里程碑和决策节点有助于明确预期，并减少规模化生产过程中的返工。其次，应投资于供应链透明度及关键原料及特殊试剂的双源筹资策略，以因应贸易政策变化及单一来源依赖所带来的风险。儘早启动供应商选择流程至关重要，以便在需要替代供应商时缩短研发週期。

我们将解释一种混合方法研究设计，该设计结合了专家访谈、技术检验和三角验证的二级资讯来源，以确保研究结果的实用性和有效性。

基础调查方法整合了多种证据来源，以确保提供可靠的实践见解。二级研究包括对科学文献、监管指导文件、行业白皮书和技术标准的系统性回顾，以建立技术和监管基础框架。一级研究包括对製造企业高管、製程科学家、监管专家、采购高管和专案经理进行结构化访谈，以收集有关营运挑战、供应商绩效和伙伴关係动态的第一手资讯。这些定性洞见辅以技术检验工作，包括近期技术转移案例分析、可比性研究和製程放大实例。

从发现到交付，核酸药物能否成功取决于能力、伙伴关係和供应链韧性的策略协调。

由于科学创新、不断变化的监管要求和营运需求的转变，核酸药物生产格局正处于变革之中。那些认识到伙伴关係关係策略意义，并投资于卓越分析、适应性生产以及贯穿弹性供应链的整合能力的企业，将更有能力将科学进步转化为可靠的临床和商业供应。转型挑战，例如关税驱动的供应调整、区域产能重组以及对先进分析技术的需求，既给营运带来挑战，也为能够提供清晰且检验的、可降低风险的规模化生产路径的企业带来机会。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 具备优化脂质奈米颗粒配方能力的可扩展mRNA生产平台的需求日益增长
  • 透过将自动化高通量筛检整合到寡核苷酸生产工作流程中来加速製程开发
  • 采用连续生产製程可提高质体DNA产量的稳定性并降低污染风险。
  • CDMO与生技公司进行策略合作，共同开发以CRISPR-Cas系统为基础的基因编辑疗法。
  • 投资于专为病毒载体生产而设计的模组化一次性生物反应器系统，以支援基因治疗研发管线。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 核酸疗法CDMO市场（依治疗类型划分）

  • DNA疗法
  • RNA疗法

9. 核酸治疗药物CDMO市场依服务类型划分

  • 分析测试和品管
  • 製造业
  • 包装/配送
  • 製程开发与最佳化

第十章：核酸治疗药物CDMO市场（依治疗应用划分）

  • 遗传性疾病
  • 感染疾病
  • 神经系统疾病
  • 肿瘤学
  • 罕见疾病

第十一章 核酸治疗药物CDMO市场（依最终用户划分）

  • 学术和研究机构
  • 生技公司
  • 製药公司

第十二章：核酸疗法CDMO市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 核酸治疗药物CDMO市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国核酸治疗药物CDMO市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AGC Biologics Inc.
    • Agilent Technologies, Inc.
    • Ajinomoto Bio-Pharma Services
    • Almac Group Ltd.
    • Biomay AG
    • BioSpring GmbH
    • Catalent, Inc.
    • Charles River Laboratories International, Inc.
    • CordenPharma International GmbH
    • Creative Biogene
    • Danaher Corporation
    • Eurofins Scientific SE
    • Evonik Industries AG
    • GenScript Biotech Corporation
    • Lonza Group Ltd.
    • Polypeptide Group AG
    • Recipharm AB
    • Rentschler Biopharma SE
    • Samsung Biologics
    • The Scripps Research Institute
    • Touchlight Group
    • Univercells Group
    • WuXi AppTec Co., Ltd.
Product Code: MRR-CA7E340319CD

The Nucleic Acid Therapeutics CDMO Market is projected to grow by USD 26.14 billion at a CAGR of 11.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.77 billion
Estimated Year [2025] USD 12.00 billion
Forecast Year [2032] USD 26.14 billion
CAGR (%) 11.71%

Framing the evolving strategic role of CDMOs in enabling complex nucleic acid therapeutic development amid accelerating scientific and regulatory demands

The nucleic acid therapeutics contract development and manufacturing landscape has entered a phase defined by rapid technological convergence and elevated strategic importance for both developers and contract partners. Recent advances in therapeutic modalities, manufacturing platforms, and regulatory expectations have elevated CDMOs from service vendors to strategic collaborators that materially influence program timelines and clinical viability. As developers pursue increasingly complex constructs, including modified oligonucleotides, viral vectors, and lipid nanoparticle formulations, demand for specialized process knowledge, stringent quality control, and adaptive manufacturing capacity has intensified.

Consequently, organizations that provide integrated capabilities spanning process development, analytical rigor, and scale-ready manufacturing are being evaluated not only on cost and capacity but also on agility, regulatory track record, and partnership models that de-risk development pathways. Stakeholders must therefore reassess their sourcing strategies, technology roadmaps, and compliance frameworks to reflect an environment where speed-to-clinic and supply continuity are as critical as technical excellence. Moving forward, the interplay between scientific innovation and pragmatic manufacturing constraints will determine which programs advance efficiently and which face protracted development timelines, making it imperative for executives to align commercial strategy with operational realities across the value chain.

Unpacking the multidimensional disruptive forces altering R&D, manufacturing modalities, regulatory expectations, and partnership models across nucleic acid therapeutics

Nucleic acid therapeutics are reshaping therapeutic paradigms, and with that transformation comes a cascade of shifts across R&D, manufacturing, and commercialization. Technological innovation is driving paradigm changes in how molecules are designed, produced, and tested; modular and continuous manufacturing approaches are replacing batch orthodoxy in many applications, while digital process controls and advanced analytics increasingly underpin quality systems and process understanding. These shifts have broadened the competency set required of contract development and manufacturing organizations, requiring investments in specialized equipment, real-time monitoring capabilities, and cross-disciplinary talent.

At the same time, regulatory expectations have matured, emphasizing lifecycle quality management, data integrity, and platform-based comparability. This maturation is influencing project planning and capitalization decisions and is prompting greater early-stage alignment between developers and manufacturers on quality by design principles. Moreover, commercial pressures are altering partnership structures: strategic alliances, risk-sharing arrangements, and capacity reservation models are becoming more common as sponsors seek to secure prioritized throughput and mitigate supply chain risk. Taken together, these transformative shifts mean that CDMOs must evolve beyond transactional relationships to become long-term strategic partners that co-design processes, anticipate regulatory challenges, and scale capabilities in lockstep with evolving modality requirements.

Assessing how tariff adjustments in 2025 have recalibrated sourcing, supplier qualification, and operational risk management across the nucleic acid therapeutics supply chain

The imposition and adjustment of tariffs by the United States in 2025 have introduced new variables into the supply and cost calculus for nucleic acid therapeutics manufacturing. Tariff measures that affect imported raw materials, specialized reagents, and certain manufacturing equipment have prompted manufacturers and sponsors to reassess sourcing strategies and to accelerate efforts to qualify alternative suppliers. As a result, procurement teams have increased scrutiny of supplier resilience and geographic diversification while manufacturing planners evaluate the trade-offs between nearshoring, onshoring, and maintaining offshore partnerships.

In practice, these tariff-driven dynamics have influenced capital allocation decisions and timetable assumptions. Sponsors that previously relied on a global sourcing model for key inputs have initiated dual-sourcing strategies and have elevated buffer management to preserve continuity for critical campaigns. Investments in supplier qualification and audits have increased, as firms seek to validate localized supply chains. Moreover, some organizations have advanced plans for regional capacity expansion to reduce exposure to cross-border cost volatility and mitigate potential lead-time disruptions. Regulatory dossiers and quality control frameworks have had to accommodate the introduction of new supplier-origin materials, requiring targeted comparability studies and additional documentation. While tariffs have not altered the scientific principles behind modality development, they have reshaped operational risk management and have heightened the strategic importance of supply chain transparency, supplier performance metrics, and contractual protections that address cross-border trade risk.

Deriving strategic implications from modality, service type, application, and end-user segmentation to target capability investments and partnership structures

A granular view of the landscape emerges when analyzing demand and capability along multiple segmentation axes. When viewed through the lens of therapeutic type, distinctions between DNA therapeutics and RNA therapeutics materially influence manufacturing workflows, analytical testing paradigms, and regulatory touchpoints; RNA modalities often demand specialized formulation expertise and cold-chain considerations, while DNA-based approaches entail distinct upstream and downstream purification challenges. From the perspective of service type, the interplay between analytical testing and quality control, manufacturing, packaging and distribution, and process development and optimization defines where value accrues; organizations that integrate end-to-end services can shorten timelines and reduce handoffs, while niche specialists retain relevance for highly technical tasks and method development.

Considering therapeutic application highlights divergent demand drivers: genetic disorders, infectious diseases, neurological disorders, oncology, and rare disorders each present unique payload requirements, dosing regimens, and clinical development risk profiles, which in turn shape manufacturing complexity and demand for tailored assays. Finally, end-user segmentation-academic and research institutes, biotechnology firms, and pharmaceutical companies-reveals differing expectations for flexibility, timelines, and regulatory support; academic partners often require adaptable, lower-volume services focused on method establishment, biotechnology firms prioritize speed and platform scalability for clinical progression, and pharmaceutical companies seek predictable quality systems and capacity for late-stage scale-up. Integrating these segmentation perspectives provides a multidimensional map to prioritize investments, align service offerings, and design partnership models that reflect client-specific needs and modality attributes.

Interpreting how regional ecosystems, regulatory frameworks, and capacity development across the Americas, EMEA, and Asia-Pacific shape CDMO strategic positioning

Regional dynamics continue to influence strategic decisions across the CDMO landscape, with distinct drivers shaping demand and capability in each geography. In the Americas, robust biotech ecosystems, venture capital activity, and a concentration of late-stage clinical programs drive demand for scalable manufacturing and stringent regulatory compliance. This environment fosters closer collaboration between sponsors and manufacturing partners on clinical-to-commercial transition planning and necessitates investments in GMP-capable facilities, regulatory affairs expertise, and supply chain resilience.

In Europe, the Middle East & Africa, evolving regulatory harmonization efforts, a strong translational research base, and growing local biomanufacturing initiatives create opportunities for regional partners to offer specialized capabilities and navigate complex cross-border regulatory landscapes. Sponsors operating in these jurisdictions often balance access to localized scientific talent with the need for interoperable quality systems and regulatory dossiers that align with multiple authorities. The Asia-Pacific region is characterized by rapid capacity expansion, a maturing supplier base for reagents and components, and significant investments by governments and private entities to build domestic manufacturing capabilities. This has encouraged the development of cost-effective manufacturing options as well as opportunities for technology transfer and joint ventures. Across all regions, supply chain transparency, compliance consistency, and the ability to execute complex analytics remain critical selection criteria for sponsors seeking to mitigate geopolitical and operational risks.

Understanding the competitive levers and partnership models that enable CDMOs to differentiate through technical depth, integrated services, and customer-aligned commercial structures

Competitive dynamics among companies serving the nucleic acid therapeutics ecosystem are increasingly defined by depth of modality expertise, integrated service offerings, and the ability to de-risk clinical translation through proven regulatory engagement. Leading providers distinguish themselves by investing in platform technologies that enable faster process development, higher product quality, and streamlined scale-up pathways. Capacity alone no longer differentiates; rather, organizations that combine robust quality systems with advanced analytics and a track record of successful transfers enjoy a competitive edge.

Partnership models are evolving: strategic alliances, co-development agreements, and capacity reservation arrangements are common among organizations seeking to secure long-term pipeline throughput. Investment in talent-particularly in process scientists, analytical chemists, and regulatory specialists-is a critical differentiator, as is the ability to demonstrate successful comparability and validation work across multiple modalities. Mergers and acquisitions continue to be a lever for accessing niche capabilities quickly, but the integration of disparate quality systems and cultures requires deliberate planning. Finally, forward-looking companies prioritize customer-centric commercial models that offer transparency around capacity, pricing mechanisms that reflect value and risk, and collaborative governance structures to resolve program-level challenges efficiently.

Actionable strategic imperatives for executive leaders to strengthen partnerships, supply resilience, digital quality, and talent for reliable nucleic acid therapeutic development

Industry leaders and program sponsors must adopt a set of pragmatic actions to align operations, partnerships, and investment plans with the evolving realities of nucleic acid therapeutic development. First, prioritize co-development frameworks that formalize early-stage collaboration between sponsors and manufacturers to accelerate process transfer and minimize downstream surprises. Establishing joint milestones and decision gates clarifies expectations and reduces rework during scale-up. Second, invest in supply chain visibility and dual-sourcing strategies for critical raw materials and specialized reagents to manage exposure to trade policy shifts and single-source dependencies. Engaging in supplier qualification early will shorten timelines when alternate sources are needed.

Third, accelerate adoption of digital quality management and process analytical technologies to enable real-time monitoring and to support regulatory dossiers that emphasize lifecycle control. These investments reduce batch failure risk and enhance comparability assessments across manufacturing sites. Fourth, align commercial agreements with operational realities by incorporating capacity reservation clauses, risk-sharing provisions, and transparent escalation mechanisms for schedule adjustments. Fifth, build internal capabilities through targeted hiring and training programs that focus on analytics, aseptic processing, and regulatory strategy, while also evaluating strategic acquisitions or partnerships to fill capability gaps rapidly. By implementing these measures, organizations can reduce program risk, preserve development momentum, and create clearer pathways from discovery to commercial supply.

Explaining the mixed-methods research design combining primary expert interviews, technical validation, and triangulated secondary sources to ensure actionable and defensible insights

The underlying research methodology synthesizes multiple evidence streams to ensure robust, actionable insights. Secondary research involved systematic review of scientific literature, regulatory guidance documents, industry white papers, and technical standards to establish baseline technical and regulatory contexts. Primary research consisted of structured interviews with manufacturing leaders, process scientists, regulatory experts, procurement leads, and program managers to capture first-hand perspectives on operational challenges, supplier performance, and partnership dynamics. These qualitative inputs were complemented by technical validation exercises, including case study analyses of recent technology transfers, comparability efforts, and process scale-up examples.

Data triangulation was applied to corroborate themes across sources, ensuring that observed patterns in capacity expansion, quality system investments, and supply chain strategies were not isolated anecdotes. The methodology also incorporated scenario analysis to evaluate the operational implications of shifts such as tariff changes, regional capacity additions, and modality-specific manufacturing complexities. Where appropriate, the research team validated assumptions through follow-up interviews and document reviews to minimize bias. Together, these methods yield a defensible synthesis that balances technical specificity with strategic relevance for decision-makers in development, manufacturing, and commercial organizations.

Synthesizing how strategic alignment of capabilities, partnerships, and supply chain resilience determines successful translation of nucleic acid therapeutics from discovery to supply

The landscape for nucleic acid therapeutics manufacturing is in flux, driven by scientific innovation, evolving regulatory expectations, and shifting operational imperatives. Organizations that recognize the strategic nature of CDMO partnerships and that invest in integrated capabilities-spanning analytical excellence, adaptive manufacturing, and resilient supply chains-will be better positioned to convert scientific advances into reliable clinical and commercial supply. Transitional pains such as tariff-driven supply adjustments, regional capacity realignment, and the need for advanced analytics present operational challenges, but they also create opportunities for providers that can offer clear, validated pathways to de-risked scale-up.

Ultimately, success will favor those who approach manufacturing as a strategic asset rather than a transactional function, establishing collaborative governance, transparent commercial terms, and continuous improvement processes that accelerate program timelines and reduce technical and regulatory risk. By aligning investment priorities with modality-specific demands and by cultivating flexible, high-integrity supply chains, sponsors and providers can create more predictable development trajectories and realize the full potential of nucleic acid therapeutics across diverse therapeutic areas.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising demand for scalable mRNA production platforms with optimized lipid nanoparticle formulation capabilities
  • 5.2. Integration of automated high-throughput screening in oligonucleotide manufacturing workflows to accelerate process development
  • 5.3. Adoption of continuous manufacturing for plasmid DNA to enhance yield consistency and reduce contamination risk
  • 5.4. Strategic partnerships between CDMOs and biotech firms for co-development of gene editing therapies using CRISPR-Cas systems
  • 5.5. Investment in modular single-use bioreactor systems tailored for viral vector production to support gene therapy pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid Therapeutics CDMO Market, by Therapeutics Type

  • 8.1. DNA Therapeutics
  • 8.2. RNA Therapeutics

9. Nucleic Acid Therapeutics CDMO Market, by Service Type

  • 9.1. Analytical Testing & Quality Control
  • 9.2. Manufacturing
  • 9.3. Packaging & Distribution
  • 9.4. Process Development & Optimization

10. Nucleic Acid Therapeutics CDMO Market, by Therapeutic Applications

  • 10.1. Genetic Disorders
  • 10.2. Infectious Diseases
  • 10.3. Neurological Disorders
  • 10.4. Oncology
  • 10.5. Rare Disorders

11. Nucleic Acid Therapeutics CDMO Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Biotechnology Firms
  • 11.3. Pharmaceutical Companies

12. Nucleic Acid Therapeutics CDMO Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nucleic Acid Therapeutics CDMO Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nucleic Acid Therapeutics CDMO Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AGC Biologics Inc.
    • 15.3.2. Agilent Technologies, Inc.
    • 15.3.3. Ajinomoto Bio-Pharma Services
    • 15.3.4. Almac Group Ltd.
    • 15.3.5. Biomay AG
    • 15.3.6. BioSpring GmbH
    • 15.3.7. Catalent, Inc.
    • 15.3.8. Charles River Laboratories International, Inc.
    • 15.3.9. CordenPharma International GmbH
    • 15.3.10. Creative Biogene
    • 15.3.11. Danaher Corporation
    • 15.3.12. Eurofins Scientific SE
    • 15.3.13. Evonik Industries AG
    • 15.3.14. GenScript Biotech Corporation
    • 15.3.15. Lonza Group Ltd.
    • 15.3.16. Polypeptide Group AG
    • 15.3.17. Recipharm AB
    • 15.3.18. Rentschler Biopharma SE
    • 15.3.19. Samsung Biologics
    • 15.3.20. The Scripps Research Institute
    • 15.3.21. Touchlight Group
    • 15.3.22. Univercells Group
    • 15.3.23. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 166. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 188. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 189. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 198. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 199. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 218. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 219. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 228. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 229. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 238. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 239. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 256. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 257. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 264. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 265. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 272. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 273. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 288. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 289. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET S